常规内科药物联合重组人生长激素治疗重症急性胰腺炎的临床疗效及其对肠黏膜屏障功能和炎性反应的影响  

Clinical effect of conventional medicine combined with recombinant human growth hormone in the treatment of severe acute pancreatitis and its impact on intestinal mucosal barrier function and inflammatory reaction of patients

作　　者：梁艳[1] 俞灿 萧志勇 谢平伯[1] 张珊 LIANG Yan;YU Can;XIAO Zhiyong;XIE Pingbo;ZHANG Shan(Department of Digestive,Xinyi City People′s Hospital,Xinyi 525300,China)

机构地区：[1]广东省信宜市人民医院消化科,525300

出　　处：《临床合理用药杂志》2022年第18期30-33,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 观察常规内科药物联合重组人生长激素治疗重症急性胰腺炎的临床疗效及其对肠黏膜屏障功能和炎性反应的影响。方法 选取2019年1月-2021年3月信宜市人民医院收治的70例重症急性胰腺炎患者为研究对象,按照随机数字表法分为对照组和试验组,各35例。对照组接受常规内科药物治疗,试验组在对照组基础上予以注射用重组人生长激素,2组均连续用药1周。比较2组临床疗效,治疗前后急性生理与慢性健康评分系统Ⅱ(APACHEⅡ)评分,临床症状(腹痛、恶心呕吐、肛门排气)改善时间和住院时间,治疗前后肠黏膜屏障指标(绒毛高度与陷窝深度)、炎性指标[肿瘤坏死因子α(TNF-α)、白介素(IL)-6、IL-8],不良反应。结果 试验组总有效率为97.14%,高于对照组的82.86%(χ^(2)=3.968,P=0.046)。治疗后,2组APACHEⅡ评分低于治疗前,且试验组低于对照组(P <0.01)。试验组腹痛、恶心呕吐改善时间、肛门排气时间及住院时间短于对照组(P <0.01)。治疗后,对照组肠黏膜陷窝深度大于治疗前,试验组肠黏膜绒毛高度、陷窝深度大于治疗前,且试验组大于对照组(P <0.05)。治疗后,2组TNF-α、IL-6、IL-8水平低于治疗前,且试验组低于对照组(P <0.01)。2组治疗期间均未发生明显药物不良反应。结论 在常规内科药物治疗基础上加用重组人生长激素治疗重症急性胰腺炎的临床疗效确切,其可更有效地改善患者的临床症状,缩短住院时间,改善肠黏膜屏障功能,减轻炎性反应,且安全性较高。Objective To explore the therapeutic effect of conventional medicine combined with recombinant human growth hormone in the treatment of severe acute pancreatitis and its impact on intestinal mucosal barrier function and inflammatory reaction of patients. Methods A sample of 70 patients with severe acute pancreatitis admitted to Xinyi City People’ s Hospital from January 2019 to March 2021,and they were divided into control group and experimental group according to randomly number table method,35 cases in each group. Patients in control gtoup were treated with conventional medicine,patients in experimental group were treated with recombinant human growth hormone based on control group,both groups were treated for 1 week. Clinical effect,APACHE Ⅱ score before and after treatment,improvement time of clinical symptoms( abdominal pain,nausea and vomiting,hepatic portal exhaust) and hospitalization time,intestinal mucosal barrier function indexes( height of villi,depth of pit) and inflammatory factors( TNF-α,IL-6 and IL-8) before and after treatment,incidence of adverse reactions were compared between the two groups. Results Total effective rate in experimental group was 97. 14%,higher than 82. 86% of control group(χ^(2)= 3. 968,P = 0. 046). After treatment,APACHEⅡ score of the two groups was lower than that before treatment,and the experimental group was lower than the control group( P < 0. 01). Improvement time of abdominal pain,nausea and vomiting,hepatic portal exhaust and hospitalization time in experimental group were shorter than those in control group( P < 0. 01). After treatment,height of villi of control group was larger than that before treatment,height of villi and depth of pit of experimental group were larger than those before treatment,and experimental group were larger than those in control group( P < 0. 05). After treatment,levels of TNF-α,IL-6,IL-8 were lower than those before treatment,and the experimental group were lower than those in control group( P < 0. 01). There was no obviously adver

关 键 词：急性胰腺炎 重组人生长激素 肠黏膜屏障 炎性因子 治疗结果 

分 类 号：R576[医药卫生—消化系统]